ATYR aTyr Pharma, Inc.
aTyr Pharma, Inc. (ATYR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $3.7K.
Where they traded
Last open-market purchase: May 27, 2026 , by SCHIMMEL PAUL .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director | Buy | 100,000 | $0.50 | $49.6K | 779,143 | |
| Shukla Sanjay | President and CEO | Sell | 3,745 | $0.98 | $3.7K | 153,553 −2.4% of holding | |
| Broadfoot Jill Marie | Chief Financial Officer | Sell | 1,558 | $0.98 | $1.5K | 37,296 −4% of holding | |
| DENYES NANCY | General Counsel | Sell | 1,118 | $0.98 | $1.1K | 33,124 −3.3% of holding | |
| SCHIMMEL PAUL | Director | Buy | 317,999 | $0.94 | $299.4K | 1,413,023 | |
| SCHIMMEL PAUL | Director | Buy | 682,001 | $0.90 | $612.4K | 1,095,024 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.